The World Market for Advair (Fluticasone Propionate + Salmeterol) to 2026: Drug Overview & Product Profiles


Dublin, June 28, 2019 (GLOBE NEWSWIRE) -- The "Advair" report has been added to ResearchAndMarkets.com's offering.

Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). The drug has anti-inflammatory and bronchodilatory effects on patients with asthma. It is administered twice daily through a dry powder inhaler device called Advair Diskus, or a pressurized metered-dose inhaler device known as Advair hydrofluoroalkane (HFA).

Twice-daily Advair was the first ICS/LABA combination to launch and quickly became the gold standard in its class and across the asthma and COPD markets. It was first launched for asthma in the UK in 1999 and was rolled out in the rest of Europe in 2000-01 and in the US in 2001. It became available in Japan in 2007. While the majority of sales are for asthma, the drug is a blockbuster for COPD as well.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Advair: Chronic obstructive pulmonary disease (COPD)
  4. Advair: Asthma

List of Figures
Figure 1: Advair for COPD - SWOT analysis
Figure 2: The authors drug assessment summary of Advair for COPD
Figure 3: The authors drug assessment summary of Advair for COPD
Figure 4: Advair sales for COPD across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Advair for asthma - SWOT analysis
Figure 6: The authors drug assessment summary of Advair in asthma
Figure 7: The authors drug assessment summary of Advair in asthma
Figure 8: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Advair drug profile
Table 2: Advair Phase III data in COPD
Table 3: Advair sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 4: Advair drug profile
Table 5: Advair Diskus pivotal trial data in asthma
Table 6: Advair HFA pivotal trial data in asthma
Table 7: Advair late-phase trial data in asthma
Table 8: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/vmb7yk

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


            

Contact Data